

510(k) SUMMARY

Submitter Information: TOTOKU ELECTRIC CO., LTD.
300 Oya, Ueda
Nagano 386-0192 Japan

Contact Person: Mikio Hasegawa, General Manager
Email: hasegawam@totoku.co.jp
Tel: +81.268.34.5469
Fax: +81.268.34.5548

Date Prepared: October 17, 2006

Device Name: 21.3-inch (54cm) Color LCD Monitor CDL2120A (CCL252i2)

Common Name: CDL2120A, CCL252i2, 2M Monitor/Display

Classification Name: Class II
(Part 892 Radiology Devices
Sec. 892.2050 Picture Archiving and Communication System)

Predicate Device: CDL2113A (K050616)

Device Description: CDL2120A (CCL252i2) is a 21.3-inch Color LCD Monitor that supports DVI video signal and provides UXGA (1600 x 1200) resolution for both landscape and portrait display.

Intended Use: 21.3-inch (54cm) Color LCD Monitor CDL2120A (CCL252i2) is to be used in displaying and viewing medical images for diagnosis by trained medical practitioners. It is not meant to be used for digital mammography.

Substantial Equivalence: CDL2120A (CCL252i2) shares the same characteristics with our predicate device CDL2113A (K050616) except for the newly-developed luminance equalizer.

TOTOKU ELECTRIC CO., LTD.

MM Company, Design Group
300 Oya, Ueda, Nagano 386-0192 Japan



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
9200 Corporate Blvd.
Rockville MD 20850

Mr. Mikio Hasegawa
General Manager
TOTOKU Electric Co., Ltd.
MM Company, Design Group
300 Oya, Ueda, Nagano 386-0192
JAPAN

DEC 4 2006

Re: K063199
Trade/Device Name: 21.3-inch (54cm) Color LCD Monitor CDL2120A (CCL252i2)
Regulation Number: 21 CFR 892.2050
Regulation Name: Picture archiving and communications system
Regulatory Class: II
Product Code: LLZ
Dated: October 17, 2006
Received: October 20, 2006

Dear Mr. Hasegawa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.



Protecting and Promoting Public Health

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 894.xxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE

510(k) Number: Not Known

Device Name: 21.3-inch (54cm) Color LCD Monitor CDL2120A (CCL252i2)

Indications for Use:

21.3-inch (54cm) Color LCD Monitor CDL2120A (CCL252i2) is to be used in displaying and viewing medical images for diagnosis by trained medical practitioners. It is not meant to be used for digital mammography.

Prescription Use ✓
(Part 21 CFR 801 Subpart D)

~~AND~~/OR

Over-The-Counter Use _____
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Nancy Brogdon
(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number R063199